Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79660 | 0.87 | MAPT (0.42) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| Water SCHEMBL3302021 | 0.84 | MAPT (0.40) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL12790540 | 0.84 | MAPT (0.40) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL17704232 | 0.82 | — | — | |
| SCHEMBL22996236 | 0.77 | MEN1 (0.36) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL17401304 | 0.77 | MEN1 (0.36) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL7921722 | 0.77 | FDPS (0.39) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL3431851 | 0.77 | MEN1 (0.36) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL23736384 | 0.75 | MEN1 (0.35) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL12958611 | 0.75 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158397-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2024-05-16 | — | — | US | claimed |
| US-11607465-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2023-03-21 | — | — | US | claimed |
| US-20230060990-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | SLOAN KETTERING INST CANCER RES (US) | 2023-03-02 | — | — | US | claimed |
| US-20210138091-A1 | USES OF LABELED HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2021-05-13 | — | — | US | claimed |
| CN-106083855-B | Purine derivatives useful as Hsp90 inhibitors | 斯隆-凯特林癌症研究院 | 2020-04-10 | — | — | CN | claimed |
| EP-3208615-B1 | USES OF LABELED HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2019-10-09 | — | — | EP | claimed |
| US-10336757-B2 | Treatment of neurodegenerative diseases through inhibition of HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2019-07-02 | — | — | US | claimed |
| US-10201623-B2 | HSP90-targeted cardiac imaging and therapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-02-12 | — | — | US | claimed |
| US-10172863-B2 | Purine derivatives useful as HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2019-01-08 | — | — | US | claimed |
| EP-3305297-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITION OF HSP90 | Sloan-Kettering Institute for Cancer Research (US) | 2018-04-11 | — | — | EP | claimed |
| US-20160310497-A1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2016-10-27 | — | — | US | claimed |
| US-9328114-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2016-05-03 | — | — | US | claimed |
| US-20140378452-A1 | Treatment of Neurodegenerative Diseases Through Inhibition of HSP90 | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2014-12-25 | — | — | US | claimed |
| US-20090298857-A1 | Treatment of Neurodegenerative Diseases Through Inhibition of HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2009-12-03 | — | — | US | claimed |
| US-6686373-B2 | ANALGESICS; ANTIINFLAMMATORY AGENT | WARNER-LAMBERT COMPANY LLC | 2004-02-03 | — | — | US | claimed |
| US-20030130277-A1 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | KAWAMURA KIYOSHI (JP) | 2003-07-10 | — | — | US | claimed |
| EP-1310498-A2 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | PFIZER INC. (US) | 2003-05-14 | — | — | EP | claimed |
| US-20240158397-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2024-05-16 | — | — | US | disclosed |
| US-20030130277-A1 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | KAWAMURA KIYOSHI (JP) | 2003-07-10 | — | — | US | disclosed |
| EP-1310498-A2 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | PFIZER INC. (US) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130277-A1 | Pyrazoloquinolinone derivatives as protein kinase C inhibitors | PRKCB, PRKCA, PRKCG | MEN1 4326/4885KMT2A 1579/4885ALDH1A1 3069/4885 |
| US-10336757-B2 | Treatment of neurodegenerative diseases through inhibition of HSP90 | HSP90AB1, HSP90B1, HSP90AA1 | MEN1 4761/4885KMT2A 3897/4885ALDH1A1 1851/4885 |
| US-10172863-B2 | Purine derivatives useful as HSP90 inhibitors | XDH, HSP90B1, HSP90AA1 | MEN1 4847/4885KMT2A 4154/4885ALDH1A1 1795/4885 |
| US-20140378452-A1 | Treatment of Neurodegenerative Diseases Through Inhibition of HSP90 | HSP90AB1, HSP90B1, HSP90AA1 | MEN1 4761/4885KMT2A 3897/4885ALDH1A1 1851/4885 |
| US-20090298857-A1 | Treatment of Neurodegenerative Diseases Through Inhibition of HSP90 | HSP90AB1, HSP90B1, HSP90AA1 | MEN1 4761/4885KMT2A 3897/4885ALDH1A1 1851/4885 |
| US-10201623-B2 | HSP90-targeted cardiac imaging and therapy | HSP90AB1, HSP90AA1, HSP90B1 | MEN1 4411/4885KMT2A 2423/4885ALDH1A1 888/4885 |
| US-20160310497-A1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | XDH, HSP90B1, HSP90AA1 | MEN1 4847/4885KMT2A 4154/4885ALDH1A1 1795/4885 |
| US-20240158397-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | HSP90B1, HSP90AB1, HSP90AB2P | MEN1 4707/4885KMT2A 4309/4885ALDH1A1 1998/4885 |
| US-11607465-B2 | Uses of labeled HSP90 inhibitors | HSP90AB1, HSP90B1, HSP90AA1 | MEN1 4299/4885KMT2A 2799/4885ALDH1A1 1352/4885 |
| US-20230060990-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES THROUGH INHIBITON OF HSP90 | HSP90B1, HSP90AB1, HSP90AB2P | MEN1 4707/4885KMT2A 4309/4885ALDH1A1 1998/4885 |
| US-20210138091-A1 | USES OF LABELED HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AA1 | MEN1 4299/4885KMT2A 2799/4885ALDH1A1 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.